![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RNF166 |
Gene summary for RNF166 |
![]() |
Gene information | Species | Human | Gene symbol | RNF166 | Gene ID | 115992 |
Gene name | ring finger protein 166 | |
Gene Alias | RNF166 | |
Cytomap | 16q24.2-q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q96A37 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
115992 | RNF166 | C04 | Human | Oral cavity | OSCC | 6.93e-04 | 3.18e-01 | 0.2633 |
115992 | RNF166 | C21 | Human | Oral cavity | OSCC | 9.89e-23 | 6.59e-01 | 0.2678 |
115992 | RNF166 | C30 | Human | Oral cavity | OSCC | 4.10e-08 | 4.38e-01 | 0.3055 |
115992 | RNF166 | C43 | Human | Oral cavity | OSCC | 1.37e-07 | 1.42e-01 | 0.1704 |
115992 | RNF166 | C46 | Human | Oral cavity | OSCC | 1.27e-06 | 1.32e-01 | 0.1673 |
115992 | RNF166 | C06 | Human | Oral cavity | OSCC | 4.73e-02 | 5.92e-01 | 0.2699 |
115992 | RNF166 | C08 | Human | Oral cavity | OSCC | 3.44e-10 | 2.81e-01 | 0.1919 |
115992 | RNF166 | SYSMH1 | Human | Oral cavity | OSCC | 2.85e-02 | 6.53e-02 | 0.1127 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF166 | SNV | Missense_Mutation | rs377640480 | c.521N>A | p.Arg174His | p.R174H | Q96A37 | protein_coding | deleterious(0.05) | probably_damaging(0.973) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | novel | c.502N>T | p.His168Tyr | p.H168Y | Q96A37 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | rs370524434 | c.536N>A | p.Arg179His | p.R179H | Q96A37 | protein_coding | tolerated(0.14) | benign(0.397) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | rs765947541 | c.344C>T | p.Ser115Leu | p.S115L | Q96A37 | protein_coding | deleterious(0) | benign(0.036) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | c.218N>T | p.Arg73Leu | p.R73L | Q96A37 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A17U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
RNF166 | SNV | Missense_Mutation | novel | c.166N>A | p.Glu56Lys | p.E56K | Q96A37 | protein_coding | tolerated(0.24) | possibly_damaging(0.82) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | novel | c.686C>A | p.Ala229Asp | p.A229D | Q96A37 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RNF166 | SNV | Missense_Mutation | novel | c.334G>A | p.Val112Met | p.V112M | Q96A37 | protein_coding | deleterious(0.02) | benign(0.101) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RNF166 | SNV | Missense_Mutation | c.404N>A | p.Pro135His | p.P135H | Q96A37 | protein_coding | tolerated(0.06) | possibly_damaging(0.862) | TCGA-BC-A112-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
RNF166 | SNV | Missense_Mutation | novel | c.235N>G | p.Lys79Glu | p.K79E | Q96A37 | protein_coding | tolerated(0.17) | possibly_damaging(0.656) | TCGA-MP-A4T8-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | navelbine | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |